Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Altimmune, Inc.
Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases.
IPO Date: May 22, 2017
Sector: Healthcare
Industry: Biotech
Market Cap: $339.03M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.31 | 4.17%
Avg Daily Range (30 D): $0.23 | 4.72%
Avg Daily Range (90 D): $0.19 | 3.75%
Institutional Daily Volume
Avg Daily Volume: 1.81M
Avg Daily Volume (30 D): 8.01M
Avg Daily Volume (90 D): 4.27M
Trade Size
Avg Trade Size (Sh.): 158
Avg Trade Size (Sh.) (30 D): 194
Avg Trade Size (Sh.) (90 D): 169
Institutional Trades
Total Inst.Trades: 1,437
Avg Inst. Trade: $1.73M
Avg Inst. Trade (30 D): $1.53M
Avg Inst. Trade (90 D): $1.21M
Avg Inst. Trade Volume: .19M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.99M
Avg Closing Trade (30 D): $1.58M
Avg Closing Trade (90 D): $1.18M
Avg Closing Volume: 223.54K
   
News
Jul 19, 2025 @ 6:30 PM
ALT Investors Have Opportunity to Join Altimmune, ...
Source: Business Wire
Jul 14, 2025 @ 2:00 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: Pomerantz Llp
Jul 3, 2025 @ 2:00 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: Pomerantz Llp
Jun 26, 2025 @ 11:00 AM
Altimmune Announces Positive Topline Results from ...
Source: Altimmune, Inc.
Apr 30, 2025 @ 8:51 AM
Will Pfizer Will Acquire Altimmune or Viking Thera...
Source: The Motley Fool
Financials
  TTM Q1 2025 Q3 2024
Basic EPS $-.26 $-.32
Diluted EPS $-.26 $-.32
Revenue $ $ .01M $ .01M
Gross Profit $ $ $
Net Income / Loss $ $ -19.58M $ -22.85M
Operating Income / Loss $ $ -21.82M $ -24.77M
Cost of Revenue $ $ $
Net Cash Flow $ $ 12.18M $ -25.65M
PE Ratio    
Splits
Sep 14, 2018:   1:30
May 05, 2017:   1:10
May 04, 2017:   1:10
Jul 25, 2007:   1:50